Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06245941
Other study ID # TQ05105-TQB3909-Ib/II-01
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 13, 2024
Est. completion date May 2027

Study information

Verified date January 2024
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Hong yan Tong, Doctor
Phone 13958122357
Email tonghongyan@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 93
Est. completion date May 2027
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Voluntarily participate in the study and signed informed consent with good compliance; - Age: 18 or above (when signing the informed consent form); Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 2; Life expectancy = 24 weeks; - Patients diagnosed with Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV-MF), or post essential thrombocythemia myelofibrosis (post-ET-MF); - Those with moderate or high risk myelofibrosis evaluated according to Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria, or those with high risk myelofibrosis according to National Comprehensive Cancer Network (NCCN) guidelines prognostic grading criteria; - Patients with poor efficacy of JAK inhibitors (for monotherapy of TQB3909, phase Ib and phase II cohort 2); - Patients who had not received JAK inhibitor treatment (for phase II cohort 1) - Spleen enlargement; - Peripheral blood primary cells and bone marrow primary cells are =10%; - No growth factor, colony stimulating factor, thrombopoietin or platelet transfusion was received within 2 weeks before the examination, and the blood routine indexes met the requirements within 7 days before the first administration - The Main organ function is normal; - Men and women of childbearing age should agree to use contraceptive measures during the study period and within 6 months after the end of the study. Exclusion Criteria: - Patients who have previously received allogeneic stem cell transplantation, or received autologous stem cell transplantation within 3 months before the first administration, or recently planned stem cell transplantation; - Patients who have previously received BCL-2 inhibitor combined with JAK inhibitor therapy; - Patients who have previously undergone splenectomy, or received splenic radiotherapy within 6 months before the first administration; - Other malignancies within 3 years prior to first administration or currently present. - Patients with multiple factors affecting oral or absorption of drugs; - Major surgical treatment or significant traumatic injury within 4 weeks prior to first administration; - Presence of congenital bleeding disorder and congenital coagulopathy; - Patients who had arterial/venous thrombosis events within 6 months before the first administration. - Have a history of mental drug abuse, or have a mental disorder. - Active or uncontrolled severe infection; - Active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection , or active Corona Virus Disease 2019 (COVID-19) infection; - Patients with grade III or above congestive heart failure, unstable angina pectoris or myocardial infarction, or arrhythmia requiring treatment, or QT interval prolongation within 6 months before the first administration; - Unsatisfactory blood pressure control despite standard therapy; - Patients with renal failure requiring hemodialysis or peritoneal dialysis; - Patients newly diagnosed with pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before the first administration; - Patients with a history of immunodeficiency disease or organ transplantation; - Patients with epilepsy requiring treatment; - Patients with uncontrolled pleural effusion, pericardial effusion or ascites; - There is a history of attenuated live vaccine inoculation within 4 weeks before the first administration, or attenuated live vaccine inoculation was planned during the study period. - People with known hypersensitivity to the study drug and excipients; - Patients diagnosed as active autoimmune diseases within 2 years before the first administration; - Those who participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first administration - Any MF treatment drugs, any immunomodulators, or any immunosuppressants were used within 2 weeks prior to the first dose - According to the judgment of the investigators, some situations seriously endanger the safety of the subjects or affect the subjects to complete the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQ05105 tablets
TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
TQB3909 tablets
TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.

Locations

Country Name City State
China The First Affiliated Hospital Zhejiang University School Of Medicine Hangzhou Zhejiang
China People's Hospital of Tianjin Tianjin Tianjin
China Xijing Hospital of the Fourth Military Medical University Xian Shaanxi
China Hennan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal tolerance dose (MTD) If dose limiting toxicity (DLT) occurs in 2 or more subjects in a given dose group, the dose level in the previous dose group is considered as MTD. Up to 2 years.
Primary Recommended phase II dose (RP2D) The RP2D is defined as the lower dose level to MTD based on the safety profile Up to 2 years
Primary 35% reduction in spleen volume (SVR35) at week 24 The proportion of subjects with a =35% reduction in spleen volume from baseline at the end of treatment at week 24 Up to 24 weeks
Secondary Optimum effective rate The proportion of subjects with at least once spleen volume reduction = 35% from baseline Up to 120 weeks
Secondary Onset time of splenic response The time interval from the first administration to the date when the spleen volume was reduced by = 35 % from baseline Up to 120 weeks
Secondary Duration of maintenance of at least 35% Reduction in Spleen Volume (DoMSR) The time between the date when the spleen volume reduction = 35% from baseline occurs for the first time and the date when the spleen volume reduction is < 35% from baseline. Up to 120 weeks
Secondary Percentage change in spleen volume from baseline Percentage change in spleen volume of subjects from baseline after treatment. Up to 60 weeks
Secondary SVR35 at week 60 The proportion of subjects with a =35% reduction in spleen volume compared to baseline after treatment at week 60. Up to 60 weeks
Secondary Myeloproliferative neoplasm - Symptom Assessment Form - Total Symptom Score (MPN-SAF-TSS) The proportion of subjects whose total symptom score of MPN-SAF TSS decreased by more than 50% from baseline. MPN-SAF-TSS is a tool for evaluating the disease burden of patients with myeloproliferative neoplasms. Each symptom is scored according to the severity, from asymptomatic (0 points) to the most serious (10 points), a total of 10 levels, the sum of 10 symptom scores is MPN-SAF-TSS score. The higher the score, the more severe the symptoms are. Up to 60 weeks
Secondary MPN-SAF-TSS decrease The time and duration when the MPN-SAF-TSS decreased by =50% compared to baseline for the first time. Up to 60 weeks
Secondary Progression-free survival (PFS) The time interval from the first dose to the date of the occurrence of any of the following events, whichever occurs first:(1) Spleen volume increased by =25% compared with the screening period ; (2) Death caused by any cause. Up to 120 weeks
Secondary Leukemia free survival (LFS) The time interval from the date of the first dose to the date of any of the following events, whichever occurs first: (1) the date of the first bone marrow smear showing the original cell =20% ;(2) The first peripheral blood smear showed that the original cells = 20% and the absolute value of the original cells =1×10^9/L and lasted for at least 2 weeks; (3) Death caused by any reason. Up to 120 weeks
Secondary Overall Survival (OS) The time from the first time the subject received treatment to death due to any cause Up to 120 weeks
Secondary Incidence of adverse events (AEs) Incidence rate of all adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0) Baseline up to 120 weeks
Secondary Severity of adverse events (AEs) Severity of all adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0) Baseline up to 120 weeks
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06397313 - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Phase 2
Not yet recruiting NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Active, not recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1